Initial IBC Submission

The initial IBC Application is intended to detail the proposed research and explain how biological toxins, infectious agents, select agents, or recombinant or synthetic nucleic acid molecules are involved. Under federal policy, a complete review by the IBC is required on an annual basis.

Initial Submission Checklist

A complete initial IBC submission increases the chance of approval. The initial IBC Application should be accompanied by documents that supplement the information provided in the application. The following information should be included with an initial submission for IBC review:

• A complete IBC Application. Responses should be clear and concise to improve readability and understanding. Complete all fields. Fields that are not applicable to the research should indicate so when possible.
• All research personnel and their study role must be defined in the IBC Application. Please note that student researchers cannot be listed as the Principal Investigator (PI) on an IBC study. A full-time faculty member must agree to accept responsibility for the project and serve as the PI. The student researcher must then be identified as the Student Investigator (SI) or in some cases, a Co-PI.
• A copy of a current curriculum vitae, biographical sketch, or resume from ALL study personnel.
• Certificates of completion for ALL required CITI modules from ALL study personnel. For more information on CITI training requirements, go to the CITI program section of this website.
• Approval of the Department Chairperson and Dean (or Associate Dean for Research). These individuals must be defined in the IBC Application so that their approval may be requested.
• A copy of the project proposal or study protocol. The information in the IBC Application should coincide with the information in the project proposal or study protocol.
• If using recombinant DNA technology (AAV’s, CRISPR, Lentiviruses, plasmids, viral vectors, etc.), include the genetic map. A Safety Data Sheet must be included if this material is classified as BSL-2 or above.
• Letters of support from entities providing resources or services for the study, if applicable. In the letter, the supporting entity must state that they are aware of the study and explain their role in the study. This does not apply to animal or substance vendors.
• The status of any applicable ancillary review(s) (IACUC, IRB, or Radiation Safety) that are associated with this study. Provide an approval letter from the committee or a statement that includes the date the application was submitted and the current review status.
• Material Transfer Agreements or Data Use Agreements if material or data will be shared with another entity. Either agreement may be initiated in the iRIS platform by completing a Material Transfer Agreement Application.